News
MyChesCo on MSN2d
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...
Zacks Investment Research on MSN4d
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback